Crest to market Whitestrips with tartar control to female demographic
WASHINGTON Crest has offered another feature to appeal to female consumers of its Crest Whitestrips Daily product. The new product is called Crest Whitestrips Daily Whitening plus Tartar Protection, which includes the ingredient sodium acid pyrophosphate that protects teeth from tartar buildup.
The idea behind the extension of the Whitening brand was to increase its status into a brand for overall health rather than a brand based solely on vanity. Their target consumers are females that have not given in to the whitening craze yet, but its tartar protection is sure to give the female demographic a boost in the store aisles. According to Mariana Sanchez, executive vice president and global equity director for Crest business, Saatchi & Saatchi, New York, the target consumer is “interested in whitening her teeth, but it is not her main priority when it comes to oral care. We know she wants more.”
The new Crest product will also be featured in two TV spots and a print ad in April, highlighting the idea that the female consumer will not just be whitening her teeth by using the product, but also helping her teeth as well.
Crest Whitestrips dominates the at-home whitening category and according to published reports, Crest Whitestrips held the top spot with sales of $63.2 million. The Crest Whitestrips Daily Whitening Plus Tartar Protection will be the seventh SKU for the Whitestrips line, and is said to retail at $39.99 for 38 doses.
Products can’t claim effectiveness against diseases, FDA says
ROCKVILLE, Md. The Food and Drug Administration on Friday announced that Brownwood Acres Foods, Cherry Capital Services—doing business as Flavonoid Sciences—and two of their top executives have signed a consent decree that effectively prohibits the companies and their executives from manufacturing and distributing any products with claims in the label or labeling to cure, treat, mitigate or prevent diseases.
The consent decree of permanent injunction is a result of the companies and their executives making unapproved drug claims and unauthorized health claims about their products, such as “Chemicals found in Cherries may help fight diabetes.” The companies are prevented from making these claims until the products are approved by the FDA as new drugs, exempt from approval as investigational new drugs, or until the claims on the products’ label and labeling comply with the law, the FDA stated.
“The FDA will not tolerate unsubstantiated health claims that may mislead consumers,” stated Margaret O’K. Glavin, associate commissioner for regulatory affairs. “The FDA will pursue necessary legal action to make sure companies and their executives manufacture and distribute safe, truthfully labeled products to consumers.”
Brownwood Acres Foods and Cherry Capital Services manufacture and distribute various products including juice concentrates, soft fruit gel capsules, fruit bars, dried fruits, liquid glucosamine and salmon oil capsules.
The decree was signed by Judge Paul Maloney on Feb. 19 in the U.S. District Court for the Western District of Michigan.
Study indicates that taking multiple NSAIDs may lead to poorer health
DURHAM, N.C. A new study released recently stated that patients taking more than one nonsteroidal anti-inflammatory drug may have poorer health quality. NSAIDs are available with or without a prescription and that is one of the problems according to the study.
These drugs are widely available, and patients may take both prescription and over-the-counter NSAIDs at the same time, either because they need more pain relief or because they don’t realize the products belong to the same class of drugs, said the study authors, who added that doctors may not know their patients are taking more than one NSAID.
The researchers, led by Stacey Kovac of Durham VA Medical Center and Duke University, found that 26 percent of the patients reported taking at least two NSAIDs (prescription, OTC or both) during the previous month, during the study, which took place from February 2002 until August 2002. These dual users scored lower than others on the physical component of a questionnaire designed to evaluate physical and mental health.
The authors suggest that physicians should keep a complete list of a patient’s medication to help identify which ones are taking more than one NSAID. Also, the researchers conclude their study by saying that, “Adequate pain management may have the potential to reduce dual use, improve patient symptoms, including physical functioning, and reduce patient safety problems.”